Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus The Michigan Lupus Epidemiology and Surveillance Program

University of Michigan, Department of Obstetrics & Gynecology, Ann Arbor, MI.
Arthritis & Rheumatology (Impact Factor: 7.76). 02/2014; 66(2). DOI: 10.1002/art.38238
Source: PubMed


To estimate the incidence and prevalence of systemic lupus erythematosus (SLE) in a sociodemographically diverse southeastern Michigan source population of 2.4 million people.

SLE cases fulfilling the American College of Rheumatology classification criteria (primary case definition) or meeting rheumatologist-judged SLE criteria (secondary definition) and residing in Wayne or Washtenaw Counties during 2002???2004 were included. Case finding was performed from 6 source types, including hospitals and private specialists. Age-standardized rates were computed, and capture???recapture was performed to estimate underascertainment of cases.

The overall age-adjusted incidence and prevalence (ACR definition) per 100,000 persons were 5.5 (95% confidence interval [95% CI] 5.0???6.1) and 72.8 (95% CI 70.8???74.8). Among females, the incidence was 9.3 per 100,000 persons and the prevalence was 128.7 per 100,000 persons. Only 7 cases were estimated to have been missed by capture???recapture, adjustment for which did not materially affect the rates. SLE prevalence was 2.3-fold higher in black persons than in white persons, and 10-fold higher in females than in males. Among incident cases, the mean ?? SD age at diagnosis was 39.3 ?? 16.6 years. Black SLE patients had a higher proportion of renal disease and end-stage renal disease (ESRD) (40.5% and 15.3%, respectively) as compared to white SLE patients (18.8% and 4.5%, respectively). Black patients with renal disease were diagnosed as having SLE at younger age than white patients with renal disease (mean ?? SD 34.4 ?? 14.9 years versus 41.9 ?? 21.3 years; P = 0.05).

SLE prevalence was higher than has been described in most other population-based studies and reached 1 in 537 among black female persons. There were substantial racial disparities in the burden of SLE, with black patients experiencing earlier age at diagnosis, >2-fold increases in SLE incidence and prevalence, and increased proportions of renal disease and progression to ESRD as compared to white patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the literature pertaining to the effect of postmenopausal hormone therapy on disease progression in women with systemic lupus erythematosus. We performed a systematic review using PubMed, Embase, and the Cochrane Central Register of Controlled Trials from January 1990 to December 2013 for observational studies and randomized clinical trials that study the effect of hormone therapy on the occurrence of flares in menopausal patients with systemic lupus erythematosus. The screenings of titles and abstracts, full text review, and risk of bias assessments were done by two independent reviewers. A total of 12,548 articles were identified. After title and abstract screening and removal of duplicates, 692 articles were retrieved for full text review. Five studies were deemed eligible for inclusion in the analysis, and the methodological quality was assessed. Two of the studies were randomized controlled trials and three were observational studies. One randomized controlled trial found that menopausal women who received hormone therapy were at a higher risk for developing minor to moderate flares of systemic lupus erythematosus. In the other four studies, there was no significant difference in systemic lupus erythematosus disease activity between hormone therapy and non-hormone therapy users. Hormone therapy in menopausal patients with systemic lupus erythematosus appears to be well tolerated. While there is some evidence supporting an increase in risk of mild to moderate flares among hormone therapy users, no association was identified between hormone therapy use and severe disease flares. In addition, hormone therapy was associated with significant improvement in menopausal symptoms and quality of life. Larger trials are required to assess the long-term effects of hormone therapy on the course of systemic lupus erythematosus in menopausal patients and to identify patient characteristics associated with an increased risk of flares in the setting of hormone therapy exposure. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    No preview · Conference Paper · Dec 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Serositis is commonly seen in systemic lupus erythematosus (SLE). Approximately 16% of patients with SLE have pleural or pericardial involvement. However, peritoneal involvement is extremely rare, and SLE with ascites as the first manifestation is an even rarer condition. This is the case report of a 19-year old male with discoid lupus who evolved with gastrointestinal symptoms as the first manifestation of the disease, characterized by significant abdominal distension and pain, asthenia, vomiting, and signs of ascites. An abdominal CT scan demonstrated ascites and marked edematous thickening of the bowel wall, which appeared as "target sign", and "double-track sign". Laboratory tests showed that his serum complement levels decreased and that he was positive for anti-nRNP/Sm antibodies, anti-Sm antibodies, anti-SS-A antibody, and anti-nuclear antibodies. The patient was treated with prednisone and chloroquine, with substantial improvement of his condition.
    No preview · Article · Dec 2014 · International Journal of Clinical and Experimental Medicine

  • No preview · Article · Feb 2014 · Arthritis & Rheumatology
Show more